384 related articles for article (PubMed ID: 27714642)
1. Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor.
Marcano AL; Ferreiro JL
Curr Atheroscler Rep; 2016 Nov; 18(11):66. PubMed ID: 27714642
[TBL] [Abstract][Full Text] [Related]
2. A Safety Evaluation of Cangrelor in Patients Undergoing PCI.
Franchi F; Rollini F; Park Y; Angiolillo DJ
Expert Opin Drug Saf; 2016; 15(2):275-85. PubMed ID: 26680584
[TBL] [Abstract][Full Text] [Related]
3. Current status of data on cangrelor.
Qamar A; Bhatt DL
Pharmacol Ther; 2016 Mar; 159():102-9. PubMed ID: 26802900
[TBL] [Abstract][Full Text] [Related]
4. Cangrelor: A Review in Percutaneous Coronary Intervention.
Keating GM
Drugs; 2015 Aug; 75(12):1425-34. PubMed ID: 26201463
[TBL] [Abstract][Full Text] [Related]
5. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
Westman PC; Lipinski MJ; Torguson R; Waksman R
Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
[TBL] [Abstract][Full Text] [Related]
6. Cangrelor: a review on pharmacology and clinical trial development.
Franchi F; Rollini F; Muñiz-Lozano A; Cho JR; Angiolillo DJ
Expert Rev Cardiovasc Ther; 2013 Oct; 11(10):1279-91. PubMed ID: 24138516
[TBL] [Abstract][Full Text] [Related]
7. Cangrelor for treatment during percutaneous coronary intervention.
Oestreich JH; Dobesh PP
Future Cardiol; 2014 Mar; 10(2):201-13. PubMed ID: 24762247
[TBL] [Abstract][Full Text] [Related]
8. Feasibility and safety of cangrelor in patients with suboptimal P2Y
Selvarajah A; Tavenier AH; Bor WL; Houben V; Rasoul S; Kaplan E; Teeuwen K; Hofma SH; Lipsic E; Amoroso G; van Leeuwen MAH; Berg JMT; van 't Hof AWJ; Hermanides RS
BMC Cardiovasc Disord; 2021 Jun; 21(1):292. PubMed ID: 34118880
[TBL] [Abstract][Full Text] [Related]
9. Cangrelor: a novel intravenous antiplatelet agent with a questionable future.
Waite LH; Phan YL; Spinler SA
Pharmacotherapy; 2014 Oct; 34(10):1061-76. PubMed ID: 25123696
[TBL] [Abstract][Full Text] [Related]
10. Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock - a Case Series.
Droppa M; Borst O; Rath D; Müller K; Gawaz M; Bhatt DL; Geisler T
Cell Physiol Biochem; 2017; 42(4):1336-1341. PubMed ID: 28700987
[TBL] [Abstract][Full Text] [Related]
11. Cangrelor for treatment of arterial thrombosis.
Walsh JA; Price MJ
Expert Opin Pharmacother; 2014 Mar; 15(4):565-72. PubMed ID: 24479981
[TBL] [Abstract][Full Text] [Related]
12. Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.
Stratz C; Nührenberg T; Valina CM; Löffelhardt N; Mashayekhi K; Ferenc M; Trenk D; Neumann FJ; Hochholzer W
Thromb Haemost; 2018 Feb; 118(2):362-368. PubMed ID: 29443372
[TBL] [Abstract][Full Text] [Related]
13. What is the Role of Cangrelor in Patients Undergoing PCI?
Droppa M; Geisler T
Curr Vasc Pharmacol; 2018; 16(5):484-489. PubMed ID: 29345586
[TBL] [Abstract][Full Text] [Related]
14. New frontiers in the management of acute coronary syndromes: cangrelor and elinogrel.
Bonadei I; Sciatti E; Vizzardi E; D'Aloia A; Raddino R; Metra M
Recent Pat Cardiovasc Drug Discov; 2014; 9(1):22-7. PubMed ID: 24915974
[TBL] [Abstract][Full Text] [Related]
15. Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives.
De Luca L; Steg PG; Bhatt DL; Capodanno D; Angiolillo DJ
J Am Heart Assoc; 2021 Jul; 10(13):e022125. PubMed ID: 34212768
[TBL] [Abstract][Full Text] [Related]
16. Cangrelor for the management and prevention of arterial thrombosis.
Storey RF; Sinha A
Expert Rev Cardiovasc Ther; 2016 Sep; 14(9):991-9. PubMed ID: 27362653
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet therapy. Cangrelor succeeds, at last, in PCI.
Storey RF
Nat Rev Cardiol; 2013 Jun; 10(6):302-4. PubMed ID: 23609175
[No Abstract] [Full Text] [Related]
18. New antiplatelet agents in the treatment of acute coronary syndromes.
Sabouret P; Taiel-Sartral M
Arch Cardiovasc Dis; 2014 Mar; 107(3):178-87. PubMed ID: 24630752
[TBL] [Abstract][Full Text] [Related]
19. Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use.
Capodanno D; Milluzzo RP; Angiolillo DJ
Ther Adv Cardiovasc Dis; 2019; 13():1753944719893274. PubMed ID: 31823688
[TBL] [Abstract][Full Text] [Related]
20. [Myocardial infarction: Role of new antiplatelet agents].
Silvain J; Bellemain A; Ecollan P; Montalescot G; Collet JP
Presse Med; 2011 Jun; 40(6):615-24. PubMed ID: 21511430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
